Table 1.

Subject characteristics and sample sizes for the Irish and the Canadian cohorts

Type of cohort	Manitoba					Cork
	CD		UC		Non-IBD control	CD		UC		Non-IBD control
Number of subjects	186		144		79	117		84		82
Gender (%female)	72.0		58.3		36.7	48.7		36.9		50.0
Age (mean±SD)	54.4±12.6		56.9±12.6		57.6±15.9	41.0±11.7		45.6±12.6		40.88±16.5
Age of disease onset (mean±SD)	30.5±11.9		36.1±13.2		NA	26.4±10.6		30.8±12.1		NA
Sample type (all time points)	Active	Inactive	Active	Inactive	Non-IBD control	Active	Inactive	Active	Inactive	Non-IBD control
Number of samples	238	340	167	324	96	55	180	61	150	179
Prior resection (%)	47.5	41.8	91.6	91.7	NA	65.5	52.2	93.4	98.0	NA
Smoking status
Non (%)	40.1		41.1		35.4	39.8		51.9		55.3
Ex (%)	44.3		44.2		24.0	48.1		41.5		14.5
Current (%)	9.5		6.1		2.1	12.0		6.6		6.1
Alcohol consumption
>2 units per day (%)	3.3		4.9		11.5	12.0		9.9		5.0
<2 units per day (%)	47.9		49.1		38.5	42.3		47.2		31.8
Non (%)	42.9		37.5		11.5	45.6		41.5		14.0
Medication
Biologics (%)	17.6	8.0	4.2	2.8	0.0	27.3	20.6	11.5	10.7	0.0
5-ASA (%)	26.9	25.0	50.9	49.4	0.0	40.0	32.8	57.4	57.3	0.0
Mercaptopurine (%)	13.9	24.1	11.4	11.4	0.0	14.5	22.2	18.0	24.7	0.0
Corticosteroids (%)	5.9	3.5	9.6	3.7	1.0	25.5	10.6	24.6	7.3	1.1
Proton pump inhibitors (%)	26.1	20.9	23.4	11.1	31.3	18.2	18.3	4.9	17.3	2.2
Other gastrointestinal drugs (%)	19.3	22.1	13.8	7.1	2.1	14.5	10.0	3.3	6.7	1.1
Antibiotics (%)	2.9	4.4	4.2	0.9	0.0	0.0	0.0	1.6	0.7	0.0
Supplements (%)	60.9	66.8	47.9	45.4	21.9	12.7	20.6	14.8	18.0	10.1
NSAIDs (%)	28.2	28.5	31.1	23.1	18.8	14.5	4.4	0.0	8.0	1.7
Diabetes drugs (%)	1.7	1.7	6.6	4.9	0.0	3.6	3.9	4.9	4.0	0.0

5-ASA, 5-aminosalicylic acid; NSAIDs, non-steroidal anti-inflammatory drugs.